BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2022 12:50:19 PM | Browse: 416 | Download: 1176
 |
Received |
|
2022-08-04 05:43 |
|
Peer-Review Started |
|
2022-08-04 05:47 |
|
First Decision by Editorial Office Director |
|
2022-10-12 01:49 |
|
Return for Revision |
|
2022-10-12 01:49 |
|
Revised |
|
2022-10-20 05:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-11-08 03:04 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-11-08 08:15 |
|
Articles in Press |
|
2022-11-08 08:15 |
|
Edit the Manuscript by Language Editor |
|
2022-11-04 12:51 |
|
Typeset the Manuscript |
|
2022-11-11 02:21 |
|
Publish the Manuscript Online |
|
2022-12-02 12:50 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Minireviews |
| Article Title |
Circulating angiotensin converting enzyme 2 and COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Tawithep Leowattana and Pathomthep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, MD, MSc, PhD, Professor, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Bangkok, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Circulating angiotensin converting enzyme 2; Coronavirus disease 2019; Disease severity; Clinical outcome; Severe acute respiratory syndrome coronavirus 2 infection |
| Core Tip |
Recently, conflicting results on circulating ACE2 (cACE2) levels in coronavirus disease 2019 (COVID-19) patients vs healthy people with low cACE2 values were published. cACE2 levels and activity were shown to be increased in severe COVID-19 patients. However, others showed no change or decreased cACE2 in severe COVID-19 patients compared to pre-pandemic controls. Furthermore, it is unclear how SARS-CoV-2 infection and recovery impact the cACE2 level. cACE2 levels increased throughout the first 2 wk of the acute phase of COVID-19. cACE2 levels, on the other hand, were elevated for 1-3 mo after infection and decreased by 4 mo of the illness course. The purpose of this review is to look at the relationship between SARS-CoV-2 and cACE2. A variety of prospective therapeutic options for inhibiting SARS-CoV-2 infection is also explored. |
| Publish Date |
2022-12-02 12:50 |
| Citation |
Leowattana W, Leowattana T, Leowattana P. Circulating angiotensin converting enzyme 2 and COVID-19. World J Clin Cases 2022; 10(34):12470-12483 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i34/12470.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i34.12470 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
